Part 6/9:
An impressive $70 billion investment by Fiser was announced, aimed at reshoring manufacturing facilities to the United States. This substantial investment will create domestic jobs, bolster local industry, and facilitate ongoing research and development efforts within the country.
The administration views this as a vital step towards strengthening America's pharmaceutical manufacturing capacity and reducing dependence on foreign imports. It also underscores a broader policy shift to prioritize U.S.-based innovation and production.